Clinical trials: Pituitary Neoplasms
Acromegaly, Pituitary Gigantism
Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism
To evaluate efficacy, safety, pharmacokinetics and pharmacodynamics of pasireotide LAR in Japanese patients with active acromegaly or pituitary gigantism.
- Trial name
- NCT01673646
- Testing
- Pasireotide LAR
- Where
- 27 sites in Japan
- Volunteers
- 33 people
- Sponsor
- Novartis Pharmaceuticals
Neoplasms, Pituitary Neoplasms
Intraoperative Imaging of Pituitary Adenomas by OTL
The primary end-point of the study is to determine the specificity and sensitivity of OTL38 in identifying pituitary adenomas when excited by an imaging probe. The investigators intend to enroll 50 patients in this study.
- Trial name
- NCT02629549
- Testing
- OTL38
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Pennsylvania
Prolactinoma
Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment
This randomized, active-controlled, parallel-arm, single-blind trial is to compare the effects of Dopamine agonists (DA) therapy targeting different established treatment strategies on glucose metabolism assessed by an oral…
- Trial name
- ProBOLIC (NCT07045935)
- Testing
- Cabergoline (Dopamine Agonist)
- Where
- Switzerland
- Volunteers
- 60 people
- Sponsor
- University Hospital, Basel, Switzerland
Pituitary Tumor, Pituitary Adenoma
Detection of PitNET Tissue During TSS Using Bevacizumab-800CW
There is a need for improved visualization of presence and extent of pituitary neuroendocrine tumor (PitNET) tissue during transsphenoidal surgery (TSS), especially in tumors invading the cavernous sinus (CS).
- Conditions
- Pituitary Tumor, Pituitary Adenoma, Pituitary Macroadenoma
- Trial name
- DEPARTURE (NCT04212793)
- Testing
- Bevacizumab-IRDye800CW, Molecular Fluorescence Endoscopy platform
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- University Medical Center Groningen
Growth Hormone Deficiency, Neoplasms
A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters
The aim of this study is to look at the long-term safety and clinical parameters of somapacitan in paediatric participants with growth hormone deficiency under routine clinical practice conditions.
- Conditions
- Growth Hormone Deficiency, Neoplasms, Diabetes Mellitus Type 2
- Trial name
- NCT06709040
- Testing
- Somapacitan
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- Novo Nordisk A/S
Recurrent Pituitary Adenomas
Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas
This is an open label study to assess the efficacy of capecitabine (CAP) and temozolomide (TMZ) in recurrent pituitary adenomas. There will be a safety run-in of at least three patients to establish any dose limiting toxicities.
- Trial name
- TMZ-Cap (NCT03930771)
- Testing
- Capecitabine, Temozolomide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Weill Medical College of Cornell University
Pituitary Tumor, ACTH-producing Pituitary Tumour
Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors
This is a phase II, open-label, 12-month pilot study in 10 patients with silent corticotroph pituitary tumors testing the hypotheses that Pasireotide long-acting release (LAR) treatment of patients with silent corticotroph…
- Trial name
- PASSILCORT (NCT02749227)
- Testing
- Pasireotide LAR
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Columbia University
Craniopharyngioma, Obesity
Multicenter Registry for Patients With Childhood.Onset Craniopharyngioma, Xanthogranuloma, Cysts of Rathke's Pouch, Meningioma, Pituitary Adenoma, Arachnoid Cysts
KRANIOPHARYNGEOM Registry 2019 will prospectively collect and descriptively analyse data on diagnostics, treatment, and follow-up of patients with craniopharyngioma.
- Trial name
- NCT04158284
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- Klinikum Oldenburg gGmbH
Pituitary Tumor
Characterization of Receptors in Non-functioning Pituitary Macroadenomas
Characterization of receptors present in non-functioning pituitary macroadenomas by Reverse Transcriptase- Polymerase Chain Reaction (RT-PCR) would assist with targeted medical therapy based on the information obtained by…
- Trial name
- NCT00852501
- Testing
- To perform RT-PCR on the tissue obtained during surgery
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cook County Health
Pituitary Adenoma, MRI
Cabergoline in the Management of Nonfunctioning Pituitary Adenoma
The goal of this clinical trial is to learn if Cabergoline (Dostinex), a dopamine agonist which has been widely used to treat hyperprolactinemia, prolactinoma for many years, works to treat nonfunctioning pituitary adenoma (NFPA)…
- Conditions
- Pituitary Adenoma, MRI, RCT
- Trial name
- NCT07034859
- Testing
- Cabergoline 0.5 MG
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Pituitary Neoplasms
Da Vinci Transoral Robotic-assisted Surgery of Pituitary Gland
Over the past 30 years, endoscopic transnasal techniques have gained a major interest, and anatomic limits have been widened in order to extend neurosurgical applications.
- Trial name
- ROBOPHYSE (NCT02743442)
- Testing
- da Vinci® Si™
- Where
- France
- Volunteers
- 8 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Hyperprolactinemia, Prolactinoma
Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole
The purpose of this study is to evaluate the use of the non-ergoline dopamine agonist ropinirole for the treatment of hyperprolactinemia in patients with idiopathic hyperprolactinemia and prolactinomas.
- Trial name
- NCT03038308
- Testing
- Ropinirole
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Columbia University
Locally Advanced Adrenal Gland Pheochromocytoma, Locally Advanced Paraganglioma
Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers
This phase II trial studies how well 177Lu-DOTATATE works in treating patients with rare endocrine cancers that have spread from where they started to nearby tissue or lymph nodes (locally advanced), spread to other places in the…
- Conditions
- Locally Advanced Adrenal Gland Pheochromocytoma, Locally Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma
- Trial name
- NCT04106843
- Testing
- Lutetium Lu 177 Dotatate
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Cushing's Syndrome
A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Patients will receive Corlux (mifepristone) daily for up to 24 weeks. Assessments of the signs and symptoms of Cushing's syndrome will be obtained.
- Trial name
- SEISMIC (NCT00569582)
- Testing
- mifepristone
- Where
- 17 sites in United States
- Volunteers
- 50 people
- Sponsor
- Corcept Therapeutics